Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Healthy Adults

Pandemic H5N1 Influenza Clinical Trial

Official title:

A Phase II, Randomized, Observer-Blind,Multi-Center, Study to Evaluate Safety, Tolerability and Immunogenicity of an Adjuvanted Cell Culture-Derived H5N1 Subunit Influenza Virus Vaccine at Two Different Formulations in Healthy Adult Subjects.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01776541
• Other study ID #: V89_04
• Status: Completed
• Phase: Phase 2
• First received: January 20, 2013
• Last updated: January 20, 2015
• Start date: January 2013
• Est. completion date: May 2014

Study information

• Verified date: January 2015
• Source: Novartis
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug AdministrationThailand: Food and Drug AdministrationAustralia: Therapeutic Goods Administration
• Study type: Interventional

Clinical Trial Summary

Evaluate Safety, Tolerability and Immune Response of Adjuvanted H5N1 Cell Culture Derived Influenza Vaccine in Adult Subjects.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 979
• Est. completion date: May 2014
• Est. primary completion date: June 2013
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 64 Years

Eligibility

Inclusion Criteria:

1. Healthy adult subjects 18 to 64 years of age,

2. Individuals willing to provide written informed consent,

3. Individuals in good health,

4. Individuals willing to allow for their serum samples to be stored beyond the study period.

Exclusion Criteria:

1. Individuals not able to understand and follow study procedures,

2. History of any significant illness,

3. History of any chronic medical condition or progressive disease,

4. Presence of medically significant cancer,

5. Known or suspected impairment/alteration of immune function,

6. Presence of any progressive or severe neurologic disorder,

7. Presence of any bleeding disorders or conditions that prolongs bleeding time,

8. History of allergy to vaccine components,

9. Receipt of any other investigational product within 30 days prior to entry into the study,

10. History of previous H5N1 vaccination,

11. Receipt of any other type of seasonal vaccination within 2 months prior to entry into the study,

12. Receipt of any other vaccine within 2 weeks prior to entry into the study

13. Body temperature =38°C.0 (=100.4° F) and/or acute illness within 3 days of intended study vaccination,

14. Pregnant or breast feeding,

15. Females of childbearing potential refusing to use acceptable method of birth control,

16. Body mass index (BMI) = 35 kg/m2,

17. History of drug or alcohol abuse,

18. Any planned surgery during study period,

19. Individuals conducting the study and their immediate family members,

20. Individuals with behavioral or cognitive impairment or psychiatric diseases.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention

Related Conditions & MeSH terms

• Influenza, Human
• Pandemic H5N1 Influenza

Intervention

Biological:
• Adjuvanted H5N1 pandemic influenza vaccine
Comparison of two doses of aH5N1c vaccine

Locations

Country	Name	City	State
Australia	46 CMAX	Adelaide	South Australia
Australia	47 Linear Clinical Research	Nedlands	Western Australia
Australia	48 Hunter Clinical Research	Newcastle	New South Wales
Thailand	80 Faculty of Tropical Medicine	Bangkok
United States	4 Benchmark Medical Research	Austin	Texas
United States	1 Miami Research Associates	Miami	Florida
United States	2 Mercy Health Research	St. Louis	Missouri
United States	3 Saint Louis University	St. Louis	Missouri

Sponsors (2)

Lead Sponsor	Collaborator
Novartis Vaccines	Department of Health and Human Services

Countries where clinical trial is conducted

United States,  Australia,  Thailand, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentages Of Subjects Achieving Hemagglutinin Inhibition (HI) Titers =40 Against A/H5N1 Strain.	The optimal aH5N1c vaccine formulation was evaluated in terms of percentages of subjects achieving HI titers =40 against homologous A/H5N1 strain, three weeks after second vaccination with either low dose or high dose of aH5N1c vaccine, according to the Center for Biologics Evaluation and Research (CBER) criterion.; CBER criterion for the adult population is met if the lower limit of the two-sided 95% confidence interval (CI) for the percentages of subjects achieving HI titer =40 meets or exceeds 70%.	Three weeks after 2nd vaccination (day 43)	No
Primary	Percentages Of Subjects Achieving Seroconversion Against A/H5N1 Strain.	Immunogenicity was measured in terms of the percentages of subjects achieving seroconversion or significant increase in HI titer against the vaccine strain, three weeks after receiving two injections of low dose or high dose of aH5N1c vaccine according to the CBER criterion.; Seroconversion is defined as either a) in subjects with a prevaccination HI titer <10, a postvaccination titer =40; or b) in subjects with prevaccination HI titer =10, a minimum four-fold rise in postvaccination HI antibody titer.; CBER criterion for the adult population is met if the lower limit of the two-sided 95% CI for the percentages of subjects achieving seroconversion for HI antibody titer meets or exceeds 40%.	Three weeks after 2nd vaccination (day 43)	No
Primary	Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AE), After Any Vaccination.	Safety was assessed using the number of subjects who reported solicited local and systemic AEs following vaccination with either low or high dose of aH5N1c vaccine.	From day 1 through day 7 after any vaccination.	No
Primary	Number of Subjects Reporting Unsolicited AEs After Any Vaccination.	Safety was assessed using the number of subjects who reported any unsolicited adverse events, adverse events possibly or probably related to study vaccine, serious adverse events (SAEs), new onset of chronic diseases (NOCDs), medically attended AEs, AEs of special interest (AESIs), AEs leading to withdrawal from study following vaccination with either low or high dose of aH5N1c vaccine.	Any unsolicited AEs - day 1 through day 22 after any vaccination. SAEs, NOCDs. medically attended AEs, AESIs, AEs leading to study withdrawal- day 1 to day 387	No
Secondary	Geometric Mean Ratios Against A/H5N1 Strain Following 2-dose Vaccination Schedule of Either Low Dose or High Dose aH5N1c Vaccine.	Immunogenicity was measured as the geometric mean ratio (GMR). The ratio of postvaccination to prevaccination HI GMTs, 3 weeks after first vaccination, 3 weeks after second vaccination and 12 months after second vaccination of either low dose or high dose of aH5N1c is reported.; The criterion is met according to the European Committee for Medicinal Products for Human Use (CHMP) criterion if the geometric mean increase GMR (day 43/day 1) in HI antibody titer is >2.5 for subjects 18-60 years of age.	Day 1; day 22; day 43 and day 387	No
Secondary	Percentages Of Subjects With HI Titers =40 Against A/H5N1 Strain.	Immunogenicity was assessed in terms of percentage of subjects achieving HI titers =40, 3 weeks after first vaccination, 3 weeks after second vaccination and 12 months after second vaccination of either low dose or high dose of aH5N1c according to the CHMP criterion.; European Licensure (CHMP) criterion is met if the percentage of subjects achieving (at day 43) HI titers =40 is >70%.	Day 1, day 22, day 43 and day 387	No
Secondary	Percentages Of Subjects Achieving Seroconversion Against A/H5N1 Strain.	Immunogenicity was assessed in terms of percentages of subjects achieving seroconversion in HI titers, 3 weeks after first vaccination, 3 weeks after second vaccination and 12 months after second vaccination of either low dose or high dose aH5N1c vaccine according to the CHMP criterion.; Seroconversion is defined as: a) for subjects with a prevaccination HI titer <10, a postvaccination titer =40; or b) for subjects with prevaccination HI titer =10, a minimum four-fold rise in postvaccination HI antibody titer.; The criterion is met according to the European (CHMP) guideline if the percentage of subjects achieving seroconversion (at day 43) is >40%.	Day 22, day 43 and day 387	No